16th International AIDS Conference Toronto, Canada - August 13 - 18, 2006

TRAPPIN-2: DISCOVERY OF A NOVEL INHIBITOR OF HIV HIGHLY ELEVATED IN HIV-RESISTANT SEX WORKERS

Int Conf AIDS. 2006 Aug 13-18;16 Abstract No. WeAa0504

Iqbal S.¹, Ball T.¹, Ao Z.¹, Maranan L.¹, Rutherford J.¹, Wachihi C.², Pak B.³, Podust V.³, Yao X.-J.¹, Plummer F.^1
1 University of Manitoba, Medical Microbiology, Winnipeg, Canada, ² University of Nairobi, Medical Microbiology, Nairobi, Kenya, ³ Ciphergen Biosystems, Fremont, United States

BACKGROUND: The HIV pandemic currently afflicts 40 million people world-wide and recently shifted its predominance, showing a higher prevalence of infection in women than men. As such, a call for a preventative microbicide was put forth as a means of protecting women from infection. In Nairobi, Kenya a group of HIV-resistant women have been identified who, despite repeated exposure, remain uninfected. Importantly, this resistance shows association with specific immune responses that protect them from infection. As most HIV transmission is through heterosexual contact, the initial site of infection in the body is the genital mucosa. Therefore, we hypothesized that the HIV-resistant women have a unique immune phenotype within their genital mucosa that confers protection from infection with HIV.

METHODS: We employed a proteomics approach to characterize the mucosal proteins found within genital tract lavage samples from HIV-resistant women and compared them to HIV-uninfected and infected women. Using surface enhanced laser desorption ionization-time of flight (SELDI-TOF) mass spectrometry (MS), we identified protein peaks of interest (or 'biomarkers') that were highly associated with the HIV-resistant group. We purified and identified one such biomarker using tandem MS and subsequently tested it for anti-HIV activity using in vitro assay systems.

RESULTS: A 6 kDa biomarker of HIV-resistance was elevated when compared to the HIV-uninfected (p<0.001) and HIV-infected (p<0.000001) study groups and subsequently identified as Trappin-2. We confirmed the over expression of Trappin-2 in HIV-resistant individuals by ELISA. Further, we show that Trappin-2 is a potent inhibitor of HIV.

CONCLUSIONS: We have identified a previously uncharacterized inhibitor of HIV using a novel proteomics approach. Importantly, elevated expression of this protein is highly associated with natural immunity to HIV infection in a HIV-resistance cohort. As such, this protein may make an ideal candidate for a component of a preventative microbicide.

Download PDF of this abstract.

2006-08-13
WeAa0504

Copyright © 2006 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.